Definium Therapeutics reported positive Phase 3 results for DT120 in GAD and MDD, maintaining a strong $1.05 billion cash position to fund operations through 2030 while preparing for a 2027 NDA filing.
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based treatments like DT120 (LSD) and DT402 (MDMA) for psychiatric disorders. As of November 2, 2026, the company had 136,899,935 common shares outstanding and is currently conducting Phase 3 clinical programs for generalized anxiety disorder and major depressive disorder.
Definium Therapeutics reported Q3 2026 financial results, highlighting a strong cash position of $1.05 billion. The company achieved positive Phase 3 topline results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for the same candidate in major depressive disorder.
Term
Q3 2026
“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”
Rob Barrow, Chief Executive Officer
“With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization. Beyond DT120, we believe DT402 represents an exciting opportunity and its initial results support continued development as we work to deliver differentiated therapies for patients with significant unmet needs.”
Definium Therapeutics CFO Brandi Roberts Sells $123K of Stock
Brandi Roberts, CFO, sold 3,377 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $123K in total on Sep 25, 2026. Shares held after the trade: 394,528 (-0.8%).
Definium Therapeutics CLO Mark Sullivan Sells $514K of Stock
Mark Sullivan, CLO, sold 14,051 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $514K in total on Sep 25, 2026. Shares held after the trade: 494,228 (-2.8%).
Definium Therapeutics Chief Commercial Officer Matthew T. Wiley Sells $113K of Stock
Matthew T. Wiley, Chief Commercial Officer, sold 3,097 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $113K in total on Sep 25, 2026. Shares held after the trade: 359,036 (-0.9%).
Definium Therapeutics CEO Robert Barrow Sells $1.15M of Stock
Robert Barrow, CEO, sold 31,550 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $1.15M in total on Sep 25, 2026. Shares held after the trade: 2,213,090 (-1.4%).
Definium Therapeutics CMO Daniel Karlin Sells $397K of Stock
Daniel Karlin, CMO, sold 10,853 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $397K in total on Sep 25, 2026. Shares held after the trade: 792,846 (-1.4%).
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder (GAD). The study met its primary endpoint with a statistically significant reduction in HAM-A scores compared to placebo (p<0.0001) and was generally well tolerated. The company plans to file an NDA in the first half of 2027 following a pre-NDA meeting with the FDA in Q4 2026.